In this episode, hosts sit down with Robert Vigersky, MD, chief medical officer of Medtronic Diabetes, for a discussion around the MiniMed 780G, including use, exclusive features, and how patients can obtain the new system.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss the implications of increased CGM access through a recent CMS expansion and take a deep dive into the latest Abbott news, including dispelling misconceptions surrounding the recall announcement.
This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.
In this episode, hosts celebrate the 10-year anniversary of the approval of the first SGLT2 inhibitor, discuss announcements related to insulin pricing, and take a deep dive into 24-week data from the MOMENTUM trial.